C-Series Breakfast :: featuring Ron Renaud, Idenix Pharmaceuticals

Share:
ACG EVENT

Event Details

When:

October 23, 2014 8 AM - 10 AM EDT

Add to Calendar

Overview

Body
C-Series Breakfast
featuring Ron Renaud, Former President & CEO, Idenix Pharmaceuticals
 
Thursday, October 23, 2014
7:00am - 9:00am
The Exchange Conference Center
212 Northern Ave, Boston MA
Parking
 
Members: 65.00 (75.00 after Oct. 20)
Non-Members: 95.00 (105.00 after Oct. 20)
 
Online registration is now closed.
Walk-ins are welcome at the door for an additional fee.
Please note the parking information for this event.
 
 
Hear Ron Renaud share his story of the sale of Idenix Pharmaceuticals, Inc. to Merck & Co., Inc. for a reported 3.8 billion, and how they successfully completed the merger, plus provide insight into the role of Private Equity and / or Venture Capital in the biotech space.
 
 
Agenda
 
7:00am Registration, Networking & Buffet Breakfast 8:00am Welcome & Opening Remarks 8:10am Ron Renaud Presentation 8:45am Q&A
 
 
About the Speaker
 
Ronald C. Renaud, Jr.
Former President & CEO
Idenix Pharmaceuticals, Inc.


Mr. Renaud served as the President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., a public biopharmaceutical company, from October 2010 until the company’s acquisition by Merck in August 2014. Mr. Renaud previously served as the Chief Financial Officer of Idenix from the time he joined Idenix in June 2007 and was additionally appointed chief business officer in June 2010. Prior to joining Idenix, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, from February 2006 to May 2007. He was a senior research analyst and global sector coordinator for JP Morgan Securities from May 2004 until February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud currently serves as a director at PTC Therapeutics (NASDAQ:PTCT) and Akebia Therapeutics (NASDAQ:AKBA). Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California.
 
 
Thank You to Our Sponsors




Annual Media Sponsor
 
Parking Information: Please park in the Standard Parking lot directly to your left as you enter the Fish Pier. Please note that this lot is pay by credit card only and ACG Boston does not validate parking. The parking at the very end of the Fish Pier next to the Exchange Conference Center is by permit only.
Hosted by: ACG
Chapter
Boston
Share: